Elicio Therapeutics, Inc.
ELTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5 | $7 | $8 | $11 |
| G&A Expenses | $0 | $3 | $3 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $8 | $10 | $10 | $13 |
| Operating Income | -$8 | -$10 | -$11 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | -$0 | -$0 | -$1 |
| Pre-Tax Income | -$10 | -$11 | -$11 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$11 | -$11 | -$14 |
| % Margin | – | – | – | – |
| EPS | -0.6 | -0.66 | -0.87 | -1.15 |
| % Growth | 9.1% | 24.1% | 24.3% | – |
| EPS Diluted | -0.6 | -0.66 | -0.87 | -1.15 |
| Weighted Avg Shares Out | 17 | 16 | 13 | 12 |
| Weighted Avg Shares Out Dil | 17 | 16 | 13 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$9 | -$10 | -$11 | -$13 |
| % Margin | – | – | – | – |